CO-VANTAGE-DATA-CENTERS
10.1.2023 14:01:55 CET | Business Wire | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced its entrance into London with the development of a 48MW £500 million campus. In addition, the company has opened a second 40MW data center on its existing Cardiff campus.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230110005323/en/
Vantage Data Centers’ LHR1 campus will include 48MW of IT capacity across two facilities. (Photo: Business Wire)
Situated on nearly five acres (two hectares) in the PowerGate neighborhood of North Acton, an established data center community in the northwest part of the city, Vantage’s London campus will total 430,000 square feet (40,000 square meters) across two 24MW multi-story data centers once fully developed. The first facility will open its doors to hyperscale customers and cloud providers in late 2024, which will mark Vantage’s 11th campus in EMEA.
“Vantage has experienced rapid growth over the past three years as we continue developing state-of-the-art data center campuses across EMEA,” said Antoine Boniface, president, EMEA at Vantage Data Centers. “With London being one of the largest data center markets in the world, this expansion further solidifies Vantage’s role at the forefront of the digital infrastructure revolution. With relatively little inventory available in London and requirements on the rise, we are ideally positioned to deliver for our customers.”
London is the largest of the FLAP (Frankfurt, London, Amsterdam and Paris) data center markets, buoyed by the U.K.’s leadership in public cloud infrastructure adoption. Findings from Structure Research indicate that hyperscale data center offerings currently account for 48% of the London market, which is projected to grow to 66% by 2027, making this a key time for Vantage to enter the arena.
“The continuing demand for data centers in London offers a prime opportunity for Vantage Data Centers to make its entrance into the highly-coveted market,” said Tim Kay, deputy director for technology, Department for International Trade in London. “Vantage’s presence in London will play a key role in enabling leading technology enterprises with additional IT capacity to support digital transformation initiatives and cloud adoption.”
In addition to the development of its London campus, Vantage has completed the first phase (12MW) of a second 40MW facility at its growing Cardiff campus, located in Wales, the second largest data center market in the U.K. The new facility boasts one of the lowest power usage effectiveness (PUE) ratios across all of Vantage’s facilities thanks in part to its extremely energy efficient indirect evaporative free cooling system, which negates the need for compressors in the cooling cycle.
Once fully developed, the 46-acre campus (19 hectares) will include three data centers totaling 148MW across 2 million square feet (186,000 square meters). Conveniently located in the U.K.’s tech corridor near the M4 and just 100 miles (160 kilometers) from London’s urban density, the campus offers numerous connectivity options with low latency between Wales and London of less than 1.5 milliseconds. The sustainable campus operates entirely on renewable energy sources.
“We are delighted to welcome customers to our newest data center in Cardiff,” said Justin Jenkins, Vantage’s chief operating officer, Europe and president, U.K. “The significant investment Vantage is making in Wales is transforming the area into one of Europe’s leading data center hubs and a top cloud region in the U.K. This is great news for the local economy as the added capacity will attract more global companies to the region, ensuring additional work for hundreds of local contractors on site and creating new permanent job opportunities.”
In December 2021, Vantage opened a corporate office in the Farringdon district of Central London to support the company’s scaling operations across EMEA.
About Vantage Data Centers
Vantage Data Centers powers, cools, protects and connects the technology of the world’s well-known hyperscalers, cloud providers and large enterprises. Developing and operating across five continents in North America, EMEA and Asia Pacific, Vantage has evolved data center design in innovative ways to deliver dramatic gains in reliability, efficiency and sustainability in flexible environments that can scale as quickly as the market demands.
For more information, visit http://www.vantage-dc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005323/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
